retatrutide type 2 diabetes trial results 2024 2025 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Lilly's triple agonist achieves 16.8%

Stay informed with the Future Outlook course (no CE credit), updated as new agents and uses emerge Easily track completions, requirements, and due dates all in one place View each states license renewal requirements at a glance Easily navigate to courses that meet your requirements (sold separately) Track progress towards your due date(s) CE that is free from pharma sponsorship and is supported by subscriptions

For others, it may now include using Northwell Direct Tier 1 insurance plans for eligible therapy services, which can make care through Insight more accessible

Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity

Storage and Handling: Protecting Your Investment Reconstitution is just the beginning

Precautions: Not recommended with insulin-sensitizing medications without supervision